These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 2029827)

  • 1. Pharmacokinetics and metabolism of allopurinol riboside.
    Shapiro TA; Were JB; Danso K; Nelson DJ; Desjardins RE; Pamplin CL
    Clin Pharmacol Ther; 1991 May; 49(5):506-14. PubMed ID: 2029827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of probenecid on the pharmacokinetics of allopurinol riboside.
    Were JB; Shapiro TA
    Antimicrob Agents Chemother; 1993 May; 37(5):1193-6. PubMed ID: 8517715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An association study of ABCG2 rs2231142 on the concentrations of allopurinol and its metabolites.
    Pilon MO; Leclair G; Oussaïd E; St-Jean I; Jutras M; Gaulin MJ; Mongrain I; Busseuil D; Rouleau JL; Tardif JC; Dubé MP; de Denus S
    Clin Transl Sci; 2022 Aug; 15(8):2024-2034. PubMed ID: 35689378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oxypurinol, allopurinol and allopurinol-1-riboside in plasma following an acute overdose of allopurinol in a patient with advanced chronic kidney disease.
    Kannangara DR; Roberts DM; Furlong TJ; Graham GG; Williams KM; Day RO
    Br J Clin Pharmacol; 2012 May; 73(5):828-9. PubMed ID: 22098112
    [No Abstract]   [Full Text] [Related]  

  • 5. [The clinical pharmacokinetics of allopurinol. 2. Allopurinol/oxypurinol pharmacokinetics following allopurinol in single doses and multiple application].
    Fenner H; Schiemann O; Gikalov I
    Arzneimittelforschung; 1985; 35(7):1093-6. PubMed ID: 4052144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the metabolism of allopurinol. Formation of allopurinol-1-riboside in purine nucleoside phosphorylase deficiency.
    Reiter S; Simmonds HA; Webster DR; Watson AR
    Biochem Pharmacol; 1983 Jul; 32(14):2167-74. PubMed ID: 6409116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orotidine accumulation in human erythrocytes during allopurinol therapy: association with high urinary oxypurinol-7-riboside concentrations in renal failure and in the Lesch-Nyhan syndrome.
    Simmonds HA; Reiter S; Davies PM; Cameron JS
    Clin Sci (Lond); 1991 Mar; 80(3):191-7. PubMed ID: 1850677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The pharmacokinetics or oral and intravenous allopurinol and intravenous oxypurinol in the horse.
    Mills PC; Dunnett M; Smith NC
    J Vet Pharmacol Ther; 1995 Dec; 18(6):451-6. PubMed ID: 8789699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and pharmacokinetics of intravenously and orally administered allopurinol in healthy beagles.
    Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M; Sawchuk RJ
    Am J Vet Res; 1997 May; 58(5):504-10. PubMed ID: 9140559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
    Walter-Sack I; Gröbner W; Zöllner N
    Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary oxipurinol-1-riboside excretion and allopurinol-induced oroticaciduria.
    Reiter S; Löffler W; Gröbner W; Zöllner N
    Adv Exp Med Biol; 1986; 195 Pt A():453-60. PubMed ID: 3728178
    [No Abstract]   [Full Text] [Related]  

  • 12. Allopurinol kinetics after massive overdosage.
    Ferner RE; Simmonds HA; Bateman DN
    Hum Toxicol; 1988 May; 7(3):293-4. PubMed ID: 3391630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects.
    Stocker SL; Williams KM; McLachlan AJ; Graham GG; Day RO
    Clin Pharmacokinet; 2008; 47(2):111-8. PubMed ID: 18193917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of two diets on pharmacokinetic parameters of allopurinol and oxypurinol in healthy beagles.
    Bartges JW; Osborne CA; Felice LJ; Koehler LA; Ulrich LK; Bird KA; Chen M
    Am J Vet Res; 1997 May; 58(5):511-5. PubMed ID: 9140560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of allopurinol and oxypurinol in human plasma and urine by liquid chromatography-tandem mass spectrometry.
    Liu X; Ni XJ; Shang DW; Zhang M; Hu JQ; Qiu C; Luo FT; Wen YG
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Dec; 941():10-6. PubMed ID: 24184830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of dietary protein on the clearance of allopurinol and oxypurinol.
    Berlinger WG; Park GD; Spector R
    N Engl J Med; 1985 Sep; 313(13):771-6. PubMed ID: 4033706
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent.
    Dixon R; Gourzis J; McDermott D; Fujitaki J; Dewland P; Gruber H
    J Clin Pharmacol; 1991 Apr; 31(4):342-7. PubMed ID: 2037706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allopurinol-1-riboside formation and HGPRT-deficiency.
    Reiter S; Löffler W; Gröbner W; Zöllner N
    Adv Exp Med Biol; 1986; 195 Pt A():447-51. PubMed ID: 3728177
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy of pyrazolopyrimidine ribonucleosides against Trypanosoma cruzi: studies in vitro and in vivo with sensitive and resistant strains.
    Berens RL; Marr JJ; Looker DL; Nelson DJ; LaFon SW
    J Infect Dis; 1984 Oct; 150(4):602-8. PubMed ID: 6436394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol.
    Day RO; Graham GG; Hicks M; McLachlan AJ; Stocker SL; Williams KM
    Clin Pharmacokinet; 2007; 46(8):623-44. PubMed ID: 17655371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.